Claire Crafter

Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity

Abstract Heterobifunctional targeted degraders (HBDs) enable potent removal of protein targets but their clinical success can be hindered by de novo toxicity inherent to their bivalent chemistry. Here we introduce a drug discovery framework that exploits high-throughput proteomic...